Skip to main content
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
433.22
+3.11 (0.72%)
At close: Aug 13, 2025

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $773.69M USD in the quarter ending June 30, 2025, with 17.26% growth. This brings the company's revenue in the last twelve months to $2.46B, up 5.01% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

Revenue (ttm)
$2.46B
Revenue Growth
+5.01%
P/S Ratio
23.25
Revenue / Employee
$1.10M
Employees
2,230
Market Cap
41.78B GBP

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 41.24B
GSK plc 31.63B
Haleon 11.02B
Smith & Nephew 4.33B
ConvaTec Group 1.72B
Hikma Pharmaceuticals 2.35B
Oxford Nanopore Technologies 183.19M
HUTCHMED (China) 439.54M
Revenue Rankings

Alnylam Pharmaceuticals News

More News